These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 26240429)

  • 1. The impact of neuroscience on society: cognitive enhancement in neuropsychiatric disorders and in healthy people.
    Sahakian BJ; Bruhl AB; Cook J; Killikelly C; Savulich G; Piercy T; Hafizi S; Perez J; Fernandez-Egea E; Suckling J; Jones PB
    Philos Trans R Soc Lond B Biol Sci; 2015 Sep; 370(1677):20140214. PubMed ID: 26240429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroethical issues in cognitive enhancement: Modafinil as the example of a workplace drug?
    Brühl AB; d'Angelo C; Sahakian BJ
    Brain Neurosci Adv; 2019; 3():2398212818816018. PubMed ID: 32166175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological cognitive enhancement: treatment of neuropsychiatric disorders and lifestyle use by healthy people.
    Sahakian BJ; Morein-Zamir S
    Lancet Psychiatry; 2015 Apr; 2(4):357-62. PubMed ID: 26360089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Focusing the Neuroscience and Societal Implications of Cognitive Enhancers.
    Savulich G; Piercy T; Brühl AB; Fox C; Suckling J; Rowe JB; O'Brien JT; Sahakian BJ
    Clin Pharmacol Ther; 2017 Feb; 101(2):170-172. PubMed ID: 27557349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroethical issues in cognitive enhancement.
    Sahakian BJ; Morein-Zamir S
    J Psychopharmacol; 2011 Feb; 25(2):197-204. PubMed ID: 20212064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lifestyle use of drugs by healthy people for enhancing cognition, creativity, motivation and pleasure.
    d'Angelo LC; Savulich G; Sahakian BJ
    Br J Pharmacol; 2017 Oct; 174(19):3257-3267. PubMed ID: 28427114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drugs, games, and devices for enhancing cognition: implications for work and society.
    Brühl AB; Sahakian BJ
    Ann N Y Acad Sci; 2016 Apr; 1369(1):195-217. PubMed ID: 27043232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Closing thoughts for cognitive enhancement.
    Kantak KM; Wettstein JG
    Handb Exp Pharmacol; 2015; 228():451-9. PubMed ID: 25977093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In search of optimal psychoactivation: stimulants as cognitive performance enhancers.
    Rozenek EB; Górska M; Wilczyńska K; Waszkiewicz N
    Arh Hig Rada Toksikol; 2019 Sep; 70(3):150-159. PubMed ID: 32597132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ethical aspects of the abuse of pharmaceutical enhancements by healthy people in the context of improving cognitive functions.
    Tomažič T; Čelofiga AK
    Philos Ethics Humanit Med; 2019 Apr; 14(1):7. PubMed ID: 31023334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Neuro-enhancement. Brain doping].
    Förstl H
    Nervenarzt; 2009 Jul; 80(7):840-6. PubMed ID: 19565292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physician attitudes towards pharmacological cognitive enhancement: safety concerns are paramount.
    Banjo OC; Nadler R; Reiner PB
    PLoS One; 2010 Dec; 5(12):e14322. PubMed ID: 21179461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A selective dopamine reuptake inhibitor improves prefrontal cortex-dependent cognitive function: potential relevance to attention deficit hyperactivity disorder.
    Schmeichel BE; Zemlan FP; Berridge CW
    Neuropharmacology; 2013 Jan; 64(1):321-8. PubMed ID: 22796428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modafinil combined with cognitive training: pharmacological augmentation of cognitive training in schizophrenia.
    Michalopoulou PG; Lewis SW; Drake RJ; Reichenberg A; Emsley R; Kalpakidou AK; Lees J; Bobin T; Gilleen JK; Pandina G; Applegate E; Wykes T; Kapur S
    Eur Neuropsychopharmacol; 2015 Aug; 25(8):1178-89. PubMed ID: 25921551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MAM-E17 rat model impairments on a novel continuous performance task: effects of potential cognitive enhancing drugs.
    Mar AC; Nilsson SRO; Gamallo-Lana B; Lei M; Dourado T; Alsiö J; Saksida LM; Bussey TJ; Robbins TW
    Psychopharmacology (Berl); 2017 Oct; 234(19):2837-2857. PubMed ID: 28744563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Use of Methylphenidate for Cognitive Enhancement in Young Healthy Adults: The Clinical and Ethical Debates.
    Koren G; Korn L
    J Clin Psychopharmacol; 2021 Mar-Apr 01; 41(2):100-102. PubMed ID: 33666399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia.
    Turner DC; Clark L; Pomarol-Clotet E; McKenna P; Robbins TW; Sahakian BJ
    Neuropsychopharmacology; 2004 Jul; 29(7):1363-73. PubMed ID: 15085092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modafinil effects on cognition and emotion in schizophrenia and its neurochemical modulation in the brain.
    Scoriels L; Jones PB; Sahakian BJ
    Neuropharmacology; 2013 Jan; 64():168-84. PubMed ID: 22820555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nootropic drugs: Methylphenidate, modafinil and piracetam - Population use trends, occurrence in the environment, ecotoxicity and removal methods - A review.
    Wilms W; Woźniak-Karczewska M; Corvini PF; Chrzanowski Ł
    Chemosphere; 2019 Oct; 233():771-785. PubMed ID: 31200137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive enhancers for the treatment of ADHD.
    Bidwell LC; McClernon FJ; Kollins SH
    Pharmacol Biochem Behav; 2011 Aug; 99(2):262-74. PubMed ID: 21596055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.